Kamada sets Q3 2026 earnings release for November 9
Interested parties can join the results discussion by telephone or through a live webcast.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
6-K
Rhea-AI Filing Summary
Kamada Ltd. (KMDA) will release financial results for the third quarter and nine months ended September 30, 2026, before U.S. markets open on November 9, 2026. Management will host a conference call at 8:30 a.m. Eastern Time that day to discuss the results and answer questions.
Key Figures
Financial results release: November 9, 2026
Conference call time: 8:30 a.m. Eastern Time
FIMI Opportunity Funds beneficial ownership: Approximately 38%
+3 more
6 metrics
Financial results release
November 9, 2026
Before the open of U.S. financial markets
Conference call time
8:30 a.m. Eastern Time
November 9, 2026
FIMI Opportunity Funds beneficial ownership
Approximately 38%
Kamada outstanding ordinary shares
FDA-approved specialty plasma-derived products
6 products
Kamada company description
U.S. plasma collection centers
3 centers
Beaumont, Houston, and San Antonio, Texas
Equine-based anti-snake venom products
2 products
Kamada company description
Key Terms
hyper-immune plasma, normal source plasma, in-licensing, life cycle management
4 terms
hyper-immune plasma medical
"support its increasing demand for hyper-immune plasma"
normal source plasma medical
"sale of normal source plasma to other plasma-derived manufacturers"
Normal source plasma is the liquid part of blood collected from healthy, screened donors that is used as raw material to make plasma-derived medicines like clotting factors and immunoglobulins. Think of it as a bulk ingredient harvested under strict safety rules; its availability and quality directly affect manufacturers’ ability to produce therapies, so investors watch supply, donor centers, and regulatory standards as indicators of production risk and revenue stability.
in-licensing technical
"through in-licensing partnerships"
Acquiring the rights to develop, make, or sell a product or technology that another company already owns, usually through a contract that spells out payments, territory and responsibilities. For investors, in-licensing can speed growth and add potential revenue without building the product from scratch—like a restaurant using a successful chef’s recipe—but it also creates ongoing costs and dependence on an outside party’s data and performance.
life cycle management technical
"commercialization and life cycle management of its proprietary products"
Managing a product, drug, service, or other business asset through all of its stages—from development and launch, through growth and maturity, to decline or retirement—so the company maximizes value and meets regulatory and market requirements. It covers plans for pricing, manufacturing, regulatory filings, patent or exclusivity strategies, updates or line extensions, and end-of-life actions. Think of it like tending a garden: planting, nurturing, pruning, and eventually replacing plants to keep the overall plot productive, which matters to investors because those choices affect future revenue, costs, and regulatory risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Kamada (KMDA) release its third-quarter 2026 results?
Kamada will release its third-quarter and nine-month results before U.S. markets open on November 9, 2026. The results cover the periods ended September 30, 2026.
What time is Kamada’s (KMDA) results conference call?
Management will host the call at 8:30 a.m. Eastern Time on November 9, 2026, to discuss the results and answer questions.
How can I join Kamada’s (KMDA) November 9, 2026 results call?
Participants can dial 1-877-407-0792 from the U.S., 1-809-406-247 from Israel, or 1-201-689-8263 internationally, using conference ID 13763380. The call will also be webcast live at https://viavid.webcasts.com/starthere.jsp?ei=1779441&tp_key=96a5dea210.
AI-generated analysis. How Rhea-AI works. Not financial advice.
